Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Page

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Journal for Immunotherapy of Cancer|January 28, 2022
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancerBrie Chun, Joanna Pucilowska, ShuChing Chang, et al.
NPJ Breast Cancer|April 20, 2022
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastasesDavid B Page, Kathryn Beal, Stefanie N Linch, et al.
Cancer Immunity|January 8, 2010
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyJianda Yuan, David B Page, Geoffrey Y Ku, et al.
NPJ Breast Cancer|November 9, 2019
If we build it they will come: targeting the immune response to breast cancerMargaret E Gatti-Mays, Justin M Balko, Sofia R Gameiro, et al.
Journal for Immunotherapy of Cancer|January 21, 2016
Novel technologies and emerging biomarkers for personalized cancer immunotherapyJianda Yuan, Priti S Hegde, Raphael Clynes, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.
Cancer Immunology Research|March 2, 2016
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Jarushka Naidoo, Katja Schindler, Christiane Querfeld, et al.
Oncoimmunology|November 3, 2018
Tumor mutational burden is a determinant of immune-mediated survival in breast cancerAlexandra Thomas, Eric D Routh, Ashok Pullikuth, et al.
NPJ Breast Cancer|March 18, 2026
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancerAlan Su, Erin C Hong, Nicole Moxon, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Journal for Immunotherapy of Cancer|January 28, 2022
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancerBrie Chun, Joanna Pucilowska, ShuChing Chang, et al.
NPJ Breast Cancer|April 20, 2022
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastasesDavid B Page, Kathryn Beal, Stefanie N Linch, et al.
Cancer Immunity|January 8, 2010
Correlation of clinical and immunological data in a metastatic melanoma patient with heterogeneous tumor responses to ipilimumab therapyJianda Yuan, David B Page, Geoffrey Y Ku, et al.
NPJ Breast Cancer|November 9, 2019
If we build it they will come: targeting the immune response to breast cancerMargaret E Gatti-Mays, Justin M Balko, Sofia R Gameiro, et al.
Journal for Immunotherapy of Cancer|January 21, 2016
Novel technologies and emerging biomarkers for personalized cancer immunotherapyJianda Yuan, Priti S Hegde, Raphael Clynes, et al.
Journal for Immunotherapy of Cancer|August 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancerLeisha A Emens, Sylvia Adams, Ashley Cimino-Mathews, et al.
Cancer Immunology Research|March 2, 2016
Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1Jarushka Naidoo, Katja Schindler, Christiane Querfeld, et al.
Oncoimmunology|November 3, 2018
Tumor mutational burden is a determinant of immune-mediated survival in breast cancerAlexandra Thomas, Eric D Routh, Ashok Pullikuth, et al.
NPJ Breast Cancer|March 18, 2026
Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancerAlan Su, Erin C Hong, Nicole Moxon, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
Pageof 7